Publications by Dr Jason Gill - ePrints

Browsing publications by Dr Jason Gill.

Newcastle Authors	Title	Year
Dr Tarek Mamdouh Abdelghany Shireen Hedya Carol De Santis Dr Jason Gill Professor Matt Wright et al.	Potential for cardiac toxicity with methylimidazolium ionic liquids	2023
Dr Rachael Redgrave Dr Emily Dookun Laura Booth Dr Maria Camacho Encina Dr Omowumi Folaranmi et al.	Senescent cardiomyocytes contribute to cardiac dysfunction following myocardial infarction	2023
Dr Rachael Redgrave Dr Maria Camacho Encina Dr Simon Tual-Chalot Dr Omowumi Folaranmi Dr Carmen Martin-Ruiz et al.	The senescence-associated secretory phenotype as a biomarker for age-related myocardial remodelling and cardiovascular disease	2023
Dr Simon Findlay Dr Jason Gill	Baseline blood pressure and development of cardiotoxicity in patients treated with anthracyclines: A systematic review	2022
Dr Alistair Brown Alaa Aljohani Fatimah Alsalem Dr Jason Gill Dr Jon Sellars et al.	Identification of Substituted Amino Acid Hydrazides as Novel Anti-Tubercular Agents, Using a Scaffold Hopping Approach	2020
Dr Simon Findlay Dr Jason Gill Professor Ruth Plummer Carol De Santis Dr Chris Plummer et al.	Chronic cardiovascular toxicity in the older oncology patient population	2019
Dr Jason Gill	Collaboration, Competition and Publication in Toxicology: views of British Toxicology Society Members	2019
Dr Rachel Oldershaw Dr Andrew Owens Rachel Telfer-Sutherland Martin Linney Rachel Liddle et al.	Human Cardiac-Mesenchymal Stem Cell-Like Cells, a Novel Cell Population with Therapeutic Potential	2019
Dr Alistair Brown Ahmed Aljohani Dr Jason Gill Dr Jon Sellars	Identification of novel benzoxa-[2,1,3]-diazole substituted amino acid hydrazides as potential anti-tubercular agents	2019
Dr Jason Gill	Trichostatin A blocks aldosterone-induced Na+ Transport and control of serum- and gulcocorticoid-inducible kinase 1 in cortical collecting duct cells	2019
Dr Jason Gill Kimberly Rockley Carol De Santis Asma Mohamed	Vascular Disrupting Agents in cancer treatment: Cardiovascular toxicity and implications for co-administration with other cancer chemotherapeutics	2019
Professor Adam Todd Dr Jason Gill	Anticancer Therapeutics: From Drug Discovery to Clinical Applications	2018
Dr Jason Gill	Aldosterone-induced Na+ Absorption is Regulated by Protein Acetylation in a Cellular Model of the Cortical Collecting Duct	2017
Kimberly Rockley Dr Jason Gill	Characterisation of Novel Molecular Mechanisms Involved in Anthracycline-Induced Cardiotoxicity	2017
Dr Jonathan Harburn Dr Jason Gill	Rationalized Computer-Aided design of Matrix Metalloprotease-Selective Prodrugs	2017
Dr Jason Gill	Anticancer RuII and RhIII Piano-Stool Complexes that are Histone Deacetylase Inhibitors	2016
Kimberly Rockley Professor Gavin Richardson Dr Jason Gill	Characterisation of novel molecular mechanisms involved in anthracycline-induced cardiotoxicity	2016
Hannah Bows Dr Jason Gill	Integration of pharmacogenetic principles as a core thread in the undergraduate pharmacy curriculum	2016
Dr Jason Gill	Oncology Activity	2016
Dr Jason Gill Kimberly Rockley	Pyridylphosphinate Metal Complexes: Synthesis, Structural Characterisation and Biological Activity	2016
Dr Jason Gill	Development of Novel Tumor-Targeted Theranostic Nanoparticles Activated by Membrane-Type Matrix Metalloproteinases for Combined Cancer Magnetic Resonance Imaging and Therapy	2014
Dr Jason Gill	MT-MMP cleavage profiling using rapid endopeptidase profiling library (REPLi)	2014
Dr Jason Gill	The Tumor-Targeted Prodrug ICT2588 Demonstrates Therapeutic Activity Against Solid Tumors and Reduced Potential For Cardiovascular Toxicity	2014
Dr Jason Gill	Antitumour activity of a duocarmycin analogue rationalised to be metabolically activated by cytochrome P450 1A1 in human transitional cell carcinoma of the bladder	2013
Dr Anja Krippner-Heidenreich Dr Jason Gill	Single-Chain TNF, a TNF Derivative with Enhanced Stability and Antitumoral Activity	2008